Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Cardiac drug potential: exploring individual and combined cardiac drugs to promote differentiation of adipose-derived stem cells into cardiomyocytes.

Alshammari H., Abuhaimed J., Alshehri S., Siyal A., Shaheen S., Al-Saud SA.

Prospective Study with a reported sample of 6 on Cardiovascular Disease, published in Mol Biol Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Mol Biol Rep (2026)
Country
Netherlands
Reported sample size
6
Source database
PubMed
PMID
41746444
PMCID
PMC12945984
DOI
10.1007/s11033-026-11553-z

Abstract (original English)

BACKGROUND: Stem cell–based cardiac regenerative medicine holds significant promise for regenerating damaged cardiomyocyte by cardiomyocyte differentiation. Among stem cell types, adipose-derived stem cells (ADSCs) are the most extensively studied due to their ease of isolation and expansion, yet current differentiation protocols remain inefficient and poorly reproducible. Given the well-established roles of certain cardiac drugs—such as Salbutamol, Ivabradine, and Entresto—their potential influence on the regulation of cardiomyocyte differentiation may provide a valuable foundation for advancing differentiation protocols. This study investigates the potential of clinically approved cardiac drugs to enhance ADSC differentiation into cardiomyocytes. METHODS: ADSCs were isolated from adipose tissue after liposuction surgery from healthy female patients (n = 6, age 23–40 year) using enzymatic methods. ADSCs at early passages (2–3) were treated with Salbutamol, Ivabradine, or Entresto for 21 days. Subsequently, RT-PCR was performed for pluripotency markers (OCT4, NANOG, and SOX2) and cardiac-specific genes (GATA4, NKX2.5, cTNNI, α-MHC). RESULT: Treatment of ADSCs with each cardiac drug independently led to downregulation of pluripotency-markers compared to controls which indicate a loss of stemness. This was accompanied by increased expression of some early cardiomyocyte markers an

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansCell DifferentiationMyocytes, CardiacFemaleAdipose TissueStem CellsAlbuterolAdultIvabradineCells, Cultured

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research